BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR (B1ME34) Price & Analysis

― Followers

B1ME34 Stock Chart & Stats

$64.68

$0.00(0.00%)

Aug 05, 2026

―

Day’s Range― - ―

52-Week Range$7.00 - $80.88

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

R$187.23B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-0.24

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,425,622,600

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR News

BeOne Medicines price target raised to $405 from $395 at Morgan Stanley

Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $405 from $395 and keeps an...

3h ago

ONC

BeOne Medicines price target raised to $454 from $424 at TD Cowen

TD Cowen analyst Yaton Werber raised the firm’s price target on BeOne Medicines (ONC) to $454 from $424...

6h ago

ONC

BeOne Medicines price target raised to $418 from $416 at Truist

Truist analyst Gregory Renza raised the firm’s price target on BeOne Medicines (ONC) to $418 from $416 and...

7h ago

ONC

BeOne Medicines price target raised to $430 from $420 at Guggenheim

Guggenheim raised the firm’s price target on BeOne Medicines (ONC) to $430 from $420 and keeps a Buy...

8h ago

ONC

BeOne Medicines price target lowered to $450 from $451 at RBC Capital

RBC Capital lowered the firm’s price target on BeOne Medicines (ONC) to $450 from $451 and keeps an...

8h ago

ONC

BeOne Medicines price target raised to $466 from $453 at Citi

Citi raised the firm’s price target on BeOne Medicines (ONC) to $466 from $453 and keeps a Buy...

9h ago

ONC

BeOne Medicines price target raised to $405 from $396 at Citizens

Citizens raised the firm’s price target on BeOne Medicines (ONC) to $405 from $396 and keeps an Outperform...

9h ago

ONC

BeOne Medicines price target raised to $407 from $403 at Barclays

Barclays raised the firm’s price target on BeOne Medicines (ONC) to $407 from $403 and keeps an Overweight...

10h ago

ONC

BeOne Medicines reports Q2 adjusted EPS $3.84, consensus $1.63

Reports Q2 revenue $1.679B, consensus $1.62B. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said, “These strong Q2...

1d ago

ONC

BeOne Medicines raises FY26 revenue view to $6.6B-$6.8B from $6.3B-$6.5B

Consensus is for FY26 revenue $ 6.51B. Raises FY26 non-GAAP operating income $1.7B-$1.8B from $1.45B- $1.55B Published first...

1d ago

ONC

Analyst Lifts BeOne Medicines Price Target to $466 on Robust BRUKINSA Growth and Pipeline Milestones

In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on BeOne Medicines, with a...

9h ago

ONC

BeOne Medicines: Buy Rating Reiterated on Strong Q2 Beat, Raised 2026 Outlook and Unchanged $395 Price Target

Analyst Sean Laaman of Morgan Stanley maintained a Buy rating on BeOne Medicines, retaining the price target of...

1d ago

ONC

B1ME34 FAQ

What was BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s price range in the past 12 months?

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR lowest stock price was $7.00 and its highest was $80.88 in the past 12 months.

What is BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s market cap?

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s market cap is R$187.23B.

When is BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s upcoming earnings report date?

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s upcoming earnings report date is Nov 05, 2026 which is in 91 days.

How were BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s earnings last quarter?

Currently, no data Available

Is BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR overvalued?

According to Wall Street analysts BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR pay dividends?

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR does not currently pay dividends.

What is BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s EPS estimate?

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR have?

BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR has 1,425,622,600 shares outstanding.

What happened to BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR?

Currently, no hedge funds are holding shares in BR:B1ME34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology